Background-(6R)-5,6,7,8-Tetrahydro-L-biopterin (BH4) is a cofactor for enzymes involved in catecholamine and nitric oxide generation whose synthesis is initiated by GTP cyclohydrolase I (GTPCH-1), encoded by GCH1. In the absence of a potent, specific GTPCH-1 inhibitor, natural BH4 deficiency caused by mutations in GCH1 in the rare movement disorder, DOPA-responsive dystonia (OMIM DYT5), offers the opportunity to study the role of endogenous BH4 in humans. Methods and Results-In 16 DOPA-responsive dystonia patients with mutations predicted to affect GTPCH-1 expression or function and in age-and sex-matched control subjects, we measured plasma biopterin and nitrogen oxides by highperformance liquid chromatography and the Griess reaction, respectively, endothelial function by brachial artery flowmediated dilation (FMD), sympathetic function by measurement of plasma norepinephrine, epinephrine, and heart rate and blood pressure in response. Cardiac function and structure were assessed by echocardiography. Plasma biopterin was lower in patients (5.76Ϯ0.53 versus 8.43Ϯ0.85 nmol/L, Pϭ0.03), but plasma NO 2 Ϫ /NO 3 Ϫ (NOx) (median, 9.06 [interquartile range, 5.35 to 11.04] versus 8.40 [interquartile range, 5.28 to 11.44] mol/L, Pϭ1) and FMD were not lower (7.7Ϯ0.8% versus 7.9Ϯ0.9%, Pϭ0.91). In patients but not control subjects, FMD was insensitive to nitric oxide synthase inhibition (FMD at baseline, 6.7Ϯ2.1%; FMD during L-NMMA infusion, 6.2Ϯ2.5, Pϭ0.68). The heart rate at rest was higher in patients, but the heart rate and blood pressure response to sympathetic stimulation did not differ in patients and control subjects despite lower concentrations of norepinepherine (264Ϯ8 pg/mL versus 226Ϯ9 pg/mL, Pϭ0.006) and epinephrine (33.8Ϯ5.2 pg/mL versus 17.8Ϯ4.6 pg/mL, Pϭ0.03) in patients. There was also no difference in cardiac function and structure. Conclusions-Sympathetic, cardiac, and endothelial functions are preserved in patients with GCH1 mutations despite a neurological phenotype, reduced plasma biopterin, and norepinepherine and epinephrine concentrations. Lifelong endogenous BH4 deficiency may elicit developmental adaptation through mechanisms that are inaccessible during acquired BH4 deficiency in adulthood. (Circ Cardiovasc Genet. 2010;3:513-522.)
Clinical Perspective on p 522
In the absence of a specific, potent inhibitor of GTPCH-1 for use in humans, it has been difficult to evaluate the precise physiological role of BH4 in sympathetic, endothelial, and cardiac functions. However, studies in cells, tissues, and rodent models and experiments assessing the effect of phar-macological doses of infused BH4 in humans have implicated a role for acquired BH4 deficiency in endothelial dysfunction that predicts and predates atherosclerosis as well as pulmonary hypertension. 3, 4 This deficiency may arise through consumption of BH4 by reaction with oxygen radicals. 5 Recently, common single-nucleotide polymorphisms in the GCH1 gene in humans have been associated with alterations in BH4 bioavailability, endothelial dysfunction in human vascular disease, 6 and altered autonomic activity, 7 but the subtle impact of common alleles can be difficult to assess reliably, and may not provide complete insight on the effect of more severe acquired BH4 deficiency implicated in endothelial dysfunction and pulmonary hypertension. We hypothesized that studies of endothelial and sympathetic function in rare patients with mutations in GCH1 leading to more profound BH4 deficiency could inform on the role of BH4 in health and disease.
Dominant mutations in GCH1 cause a neurological disorder called DOPA-responsive dystonia (DRD) (OMIM:DYT5). The neurological signs and symptoms reflect reduced tyrosine hydroxylase activity in the brain, 8, 9 which, in turn, results in reduced DA and 5-HT synthesis. The neurological sequelae are corrected by supplementation with oral L-DOPA, but the impact of GCH1 mutations on NO biosynthesis in the endothelium and catecholamine synthesis in the sympathetic nervous system, which would be unaffected by L-DOPA supplementation, have not previously been studied. We assessed endothelial, sympathetic, and cardiac functions on patients with mutation-confirmed DRD to better evaluate the role of endogenous BH4 deficiency in humans.
Methods
All patients and healthy control subjects provided written informed consent. The studies were approved by the University College London Hospitals and National Hospital for Neurology and Neurosurgery joint research ethics committee.
Identification of Patients With DRD and the Mutations
We conducted exon sequencing of 40 patients from the Movement Disorder Clinic at the National Hospital for Neurology and Neurosurgery, London, United Kingdom, with the clinical syndrome of DRD and identified 16 patients with mutations in GCH1 from 10 families, 3 of whom with no other available family member or family history. Sequencing primers and other details are provided in the online-only Data Supplement.
Modeling of the Effects of GCH1 Mutations on GTPCH-1 Structure and Function
The crystal structure of human GTPCH-1 had not been solved at the time of these experiments. However, there is homology at sequence and amino acid level with rat GTPCH 1 that is sufficient to allow inference on the likely effects of mutations in human GCH1 of GTPCH-1 structure/function. The stimulatory conformation of GTPCH-1 (PDB code 1is8) was used to construct the illustrations in the present study using PyMOL program (W.L. DeLano, The PyMOL Molecular Graphics System (2002) DeLano Scientific, Palo Alto, Calif; http://www.pymol.org).
Measurement of Total Biopterin, NO
2 ؊ /NO 3 ؊
(NO x ), NE, and Epinephrine Concentrations
Total plasma biopterin concentration was measured using the method of Fukushima and Nixon. 10 In brief, reduced pterins were oxidized using 3% iodide solution (3% iodine in 6% KI) after removal of proteins with 60% perchloric acid. Total biopterin was detected by fluorescence set at 360 nm excitation and 440 nm emission using high-performance liquid chromatography (HPLC), Spherisorb ODS-1 column with a 5% methonal mobile phase run at 1 mL/min flow rate. NO 2 Ϫ /NO 3 Ϫ (NO x ) was measured using the Griess assay, as described previously. 11 Because of the rarity of the condition, the participants in the current study were recruited from all over the United Kingdom for 2 separate attendances over 24-hour and 36-hour periods in London. We thought it to be unduly onerous to ask the participants to maintain themselves on a nitrate-free diet when they were already omitting their routine medication for the purposes of the study and were undergoing detailed tests of endothelial, cardiac, and autonomic function. We therefore measured NO 2 Ϫ /NO 3 Ϫ (NO x ) using the Griess method on an unrestricted diet. Concentrations of norepinephrine and epinephrine were determined in plasma using a reverse-phase ion-pair HPLC with electrochemical detection, after a solvent extraction with heptane and a reextraction into acetic acid. This assay was developed and carried out in the Neurovascular Medicine Unit at St Mary's Hospital Medical School/ Imperial College of Science, Technology and Medicine, London, United Kingdom, using a modification of the method described by Smedes et al. 12 
Assessment of Vascular Endothelial Function by Flow-Mediated Dilation
Subjects lay supine on a bed in a temperature-controlled room (temperature 21°to 24°C). Blood pressure and heart rate were recorded after a 10-minute rest period. Flow-mediated dilation (FMD) was assessed in the brachial artery with the pneumatic cuff placed around the upper forearm and in the radial artery with the cuff placed at the wrist when brachial artery infusions were being undertaken. The brachial/radial artery was imaged using highresolution ultrasound, with a 5-to 10-MHz linear array transducer (Acuson XP10). Longitudinal, ECG-gated end-diastolic images were recorded continuously before, during, and after cuff inflation to 300 mm Hg. Pulsed-wave Doppler was also recorded continuously to assess blood flow at baseline and immediately after cuff release and is expressed as the ratio of change from the baseline. The brachial/ radial diameter was measured offline using edge detection software (Brachial Tools, MIA, Coraville, Iowa) from images acquired at 3-second intervals throughout the FMD study protocol (baseline, 1 minute; cuff inflation, 5 minutes; post-cuff deflation, 5 minutes) and calculated as the maximum change post hyperemia in relation to the baseline expressed as percentage. The dilator response of the brachial artery to administration of sublingual glyceryl trinitritate (25 g) was used to assess endothelium-independent dilation. FMD was also measured in the radial artery after infusion of L-NMMA to assess the NO-dependent component of endothelial function. For these studies, an arterial cannula was inserted into the brachial artery of the nondominant arm under 2% Lidocaine anesthetic (East Anglia Pharmaceutical, East Anglia, United Kingdom) and an infusion of 0.9% sodium chloride solution was commenced at a rate of 0.5 mL/min. Endothelium-dependent FMD of the radial artery was measured in 8 patients with DRD and 8 healthy control subjects as described previously both in the absence and presence of L-NMMA. Twenty minutes after the initial assessment of FMD, a freshly made 4 mol/min solution of L-NMMA was administered intra-arterially. After 10 minutes of L-NMMA infusion, FMD was then reassessed while the infusion continued.
Assessment of Cardiovascular Autonomic Function
Heart rate and blood pressure were recorded (1) supine and then during a 10-minute, 60°head-up tilt; (2) before and during handgripping of an inflated, rolled-up cloth sphygmomanometer to one-third of maximum applied pressure; (3) before and during a 2-minute mental arithmetic test; (4) before and during immersion of the right hand in a bucket of crushed ice for 90 seconds; and (5) after 5 minutes of standing unaided in the same position. A venous cannula was inserted in an antecubital vein of the right arm to obtain venous blood 
Assessment of Structure and Cardiac Function
The subjects were positioned supine on the left lateral side for cardiac imaging, with a 3-lead ECG attached to the chest for continuous monitoring. An ultrasound probe was used to take parasternal and apical views. Echocardiography studies were performed using a M3S transducer with a Vivid 7 Dimension echocardiography machine (GE ultrasound system). Second-generation harmonic tissue imaging and quantitative profiles for tissue Doppler imaging TDI and strain and strain rate were performed. Cardiac diameters were assessed in the parasternal long-and short-axis views in M-mode. In the apical views, TDI measured mitral and tricuspid annular velocities. These views were also used to assess myocardial velocity left ventricular, right ventricular, and septal velocities, strain and strain rates. In addition, 4 other views were taken to visualize and assess the right ventricle.
Statistical Analysis
The data were analyzed using commercially available computer software; Graph Pad Prism version 4; D'Agostino and Pearson Omnibus normality tests were used to test for normal distribution of data. Continuous data were expressed as mean, standard deviation, or standard error of mean or 95% confidence interval. Categorical data were reported as absolute numbers and proportion. Differences between groups were evaluated using Student paired or unpaired t test or Mann-Whitney test as appropriate. Between-group differences during 2 experimental study periods were evaluated using 2-way ANOVA. Statistical significance was defined as probability value Ͻ0.05.
Results

Missense, Stop Codon, and Splice Site Mutations in GCH1 Cause a DYT5 Phenotype
We used exon sequencing to identify mutations in GCH1 in 16 patients from 10 families with the neurological phenotype (Table 1 and online-only Data Supplement Figure 1 ). Figure 1A and 1B show the overall architecture of the stimulatory complex between rat GTPCH-1 and GFRP as determined by x-ray crystallography (see Methods). 13 The structural effects of the 5 amino acid substitutions were assessed by inspecting the likely impact of the modifications of the corresponding rat amino acids residues using the PyMOL program. Features evaluated included the size of any amino acid substitution, charge changes, hydrogen bonding ability, and backbone flexibility. Mutations that lead to premature termination of translation of GTPCH-1 would be predicted to result in a more severe functional disturbance as is the case in Glu61STOP mutation, which occurs very proximally in the growing amino acid chain. This mutation results in loss of 30 residues of the protein, including parts involved in pentamer and decamer formation. The stacking of the GTPCH-1 pentamer would be predicted to be affected in the case of the valine for alanine substitution at position 74 because this mutation affects a residue lying at the interface of two GTPCH-1 pentamers. Valine is a larger amino acid than alanine and would be expected to distort the surface of each pentamer, compromising their packing ( Figure 1C ). Both Arg 88 and Leu 91 lie at the interface between GTPCH1 pentamers ( Figure 1D ), and their substitutions could affect decamer formation. Substitution of Arg88 by proline would destabilize the decamer by loss of hydrogen bonds to Glu142 from the other pentamer, whereas substitution of Leu 91 would introduce an extra unpaired positive charge. Valine 191 lies on the surface of the GTPCH-1, and replacing it with the larger isoleucine side chain should not affect folding. However, in the complex, a leucine side chain from GFRP (shown in red in Figure 1E ) is only 4 Å away from Val 191, and its interaction with the larger isoleucine may affect complex formation. Valine 204 is buried in the hydrophobic core of the GTPCH-1 monomer, and there is insufficient space here for the larger isoleucine side chain without some distortion to the structure. The consequences of such a mutation are predicted to be variable with anything from a nonfolding protein to a readjusted but still active structure. Met211 is part of a hydrophobic patch at the interface between the GTPCH1 pentamers and lies adjacent to a zinc-binding site ( Figure 1F ). Its replacement with valine may create an unfavorable "hole" in the interface or a more subtle effect such as shielding the metal site may be perturbed, although it is not clear whether this mutation is sufficient to lead to loss of function.
Patients With GCH1 Mutations Have Lower Circulating Biopterin But Preserved Plasma NOx Concentrations
Total plasma biopterin concentration was measured as an index of BH4 synthesis by acid oxidation of the plasma samples and HPLC detection. Total biopterin was significantly lower in 9 patients with GCH1 mutations compared with 14 healthy control subjects (5.76Ϯ0.53 versus 8.43Ϯ0.85 nmol/L, difference between meansϭ2.67Ϯ1.12, Pϭ0.03) (Figure 2 ). The mean total biopterin concentration in patients grouped by the type of GCH1 mutation (nonsyn- 
Brachial Artery FMD Is Preserved in Patients With GCH1 Mutations
FMD in the brachial artery was assessed as a noninvasive measure of endothelial function. FMD was 7.7Ϯ0.8% and 7.9Ϯ0.9% in patients with DRD (nϭ16) and healthy control subjects (nϭ16), respectively (difference between means, 0.15Ϯ1.2, Pϭ0.91) ( Figure 3A) . The endothelium-independent vasodilator response to glyceryl trinitritate was also no different: 8.1Ϯ1.2% and 9.3Ϯ1.0%, patients with DRD (nϭ16) and healthy control subjects (nϭ14), respectively (difference between means, 1.2Ϯ1.6, Pϭ0.45) ( Figure 3B ). To assess the NO-dependent component of FMD, experiments were repeated in the presence of continuous intrabrachial infusion of 4 mol/min of L-NMMA, the specific inhibitor of NO synthase. For these studies, FMD was assessed in the radial artery. L-NMMA infusion resulted in a significant inhibition of FMD in healthy control subjects (FMD at baseline, 7.6Ϯ1.5%; FMD during L-NMMA infusion, 5.1Ϯ1.5; mean difference, 2.3; Pϭ0.03) ( Figure 4A ). However, L-NMMA had no effect on FMD in patients with DRD (FMD at baseline, 6.7Ϯ2.1%; FMD during L-NMMA infusion, 6.2Ϯ2.5%; mean difference, 0.5; Pϭ0.68, nϭ8) ( Figure 4B ).
There was no difference in the baseline vessel diameter, velocity time integral (VTI)%, baseline blood flow, or flow during hyperemia (data not shown).
Reduced Sympathetic Neurotransmitter Plasma Concentration But Preserved Sympathetic Function in Patients With GCH1
In the supine position, the plasma concentration of NE (226Ϯ9 pg/mL versus 264Ϯ8 pg/mL, Pϭ0.006, nϭ12 pa- tients versus 14 control subjects) and epinephrine (17.8Ϯ4.6 pg/mL versus 33.8Ϯ5.2 pg/mL, Pϭ0.03, nϭ10 patients versus 14 control subjects) was lower in patients with DRD than in control subjects. There was also a blunted NE response to tilt (285Ϯ13 pg/mL in patients with DRD versus 397Ϯ23 pg/mL healthy control subjects; 2-way ANOVA for subject group, PϽ0.0001) ( Figure 5A ). The rise in plasma epinephrine concentration to tilt was also significantly blunted in the patients with DRD, with an epinephrine concentration of 23.0Ϯ5.3 pg/mL in the patients compared with 53.7Ϯ7.5pg/mL in the healthy control subjects (2-way ANOVA for subject group, Pϭ0.0006) ( Figure 5B ).
Despite these biochemical differences, there was no difference between the patients with DRD and control subjects in the blood pressure or heart rate response to sympathetic activation in response to standing unaided isometric exercise, cold pressor, and mental arithmetic tests (Table 3 and online-only Data Supplement Figure 2) . Although in the tilt-table test there was a trend toward a higher heart rate at baseline and in response to tilt in patients (2-way ANOVA, for heart rate, Pϭ0.08 for subject group; Pϭ0.001 for tilt; and Pϭ0.97 for subject group-tilt interaction), the blood pressure responses did not differ ( Figure 6A and 6B ).
Normal Cardiac Morphology in Patients With Mutations in GCH1
In view of pulmonary hypertension and right ventricular hypertrophy in animal models of BH4 deficiency, we performed ECG and transthoracic echocardiography in patients with DRD and control subjects. The 9 patients with DRD and 8 control subjects studied were all in sinus rhythm with normal complexes and morphology. Moreover, no significant differences were seen in 9 patients with DRD compared with 8 healthy control subjects in echocardiographic indices of right heart structure and function (Table 4 ). No differences were expected in indices of the left heart function, and analysis of the data on the left heart confirmed this.
Discussion
BH4 is an essential cofactor for synthesis of the aromatic amino acid neurotransmitters NE, 5HT, and DA as well as NO. BH4 deficiency has been linked to reduced NO bioavailability and endothelial dysfunction. Impaired endotheliumdependent vasodilation is seen in people with high blood pressure, 14 diabetes, 15 high cholesterol, 16 and those who smoke, 17 where supplementation with BH4 improves the vasodilator response. This has been taken as the evidence for BH4 deficiency as a mechanism underlying endothelial dysfunction. Animal studies are also suggestive of a link between decreased BH4 and endothelial dysfunction. 18 -22 Equally, supplementation of BH4 either orally, or by selective over expression of GCH1 gene targeted to endothelial cells, has been shown to improve the endothelial dysfunction and maintain systemic and tissue BH4 concentrations. 18, 21, 22 However, the lack of a potent and specific inhibitor for GTPCH-1 has limited the potential for obtaining direct evidence on the effect of BH4 on vascular and autonomic function in humans. Evidence from animal studies using hph-1 mice (rendered BH4-deficient by mutagenesis) or mice conditionally overexpressing GCH1 in the endothelium suggests a role for BH4 deficiency in endothelial dysfunction in the development of pulmonary hypertension and right ventricular hypertrophy. 3, 4 The hph-1 mouse also recapitulates some of the biochemical/neurological abnormalities in patients with GCH1 mutation.
Patients with DRD and GCH1 mutations studied here provided an opportunity for the first investigation of the effects of inherited BH4 deficiency on vascular, autonomic, and cardiac functions. Despite the presence of mutations predicted to have substantial effect on GTCH-1 structure and function, as well as a significantly lower plasma total biopterin, NE, and epinephrine concentrations, patients with DRD had preserved endothelial and sympathoadrenal autonomic function.
Baseline FMD, a validated measure of vascular endothelial function (known to be mediated largely by NO, 23 was also preserved in the patients with DRD, as was the plasma concentration of NO 2 Ϫ /NO 3 Ϫ (NO x ). At face value, this might be taken as evidence for preserved NO synthesis in these patients. However, the failure to detect a difference in NO 2 Ϫ /NO 3 Ϫ (NO x ) between the groups may have arisen for several reasons, including a real absence of difference in NO production between the groups; the insensitivity of the measure; the lack of statistical power; or the confounding effect of dietary nitrate consumption because the subjects maintained an unrestricted diet. Taken in isolation, these biochemical data can therefore neither confirm nor refute the possibility that a deficiency of BH4 affects NO production, which is not a specific limitation of the current study but rather a more general limitation of the methods available to measure NO synthesis in vivo in humans. Potential explanations for the preserved FMD in patients with DRD include the absence of an effect on NO synthesis or that a non-NO mediator is upregulated in patients with DRD and is responsible for the preservation of the endothelial function. We tested this hypothesis by studies of the effect of continuous infusion of the NOS-selective inhibitor L-NMMA on radial FMD. In these studies, the FMD response was diminished by L-NMMA in the healthy control group, but in patients with DRD it did not alter the dilator response to the flow stimulus. The completely NO-independent vasodilation in DRD patients is therefore consistent with reduced vascular NO synthesis and upregulation of another endothelial mediator such as prostacyclin, hydrogen peroxide (possibly NOSderived), or an endothelium-derived hyperpolarizing factor of which a cytochrome p450-derived metabolite, K ϩ ions, and C-type natriuretic peptide are potential candidates. Evidence on the precise mediator involved would require additional studies with coinfusion of selective inhibitors of these pathways, but, because of the already intensive nature of the studies, this could not be conducted as part of the current series of experiments.
Although we detected a lower plasma BH4 concentration in DRD patients than in control subjects, It would also have been of interest to measure the BH4 concentration in tissues, which has previously been shown to be lower in vascular tissues from patients with atherosclerosis undergoing coronary artery bypass surgery. 24 It would also have been of interest to measure GTPCH-1 activity, perhaps in circulating lymphocytes, and to relate this to mutation type. However, because of the already intensive nature of the studies conducted and the inaccessibility of the relevant tissues of interest (vascular, cardiac, and neuronal) in this group of patients, these analyses were beyond the scope of the current investigation. Previous studies have reported reduced GTPCH-1 activity in cultured skin fibroblasts from patients with DRD. 25 Despite the diminished NE and epinephrine plasma concentrations, the sympathoadrenal response in the patients with DRD was preserved. Lower concentrations of systemic NE are not necessarily correlated with abnormal sympathoadrenal function. Plasma NE and epinephrine concentrations are determined by the rate of their release into blood stream and clearance. Spillover concentrations relate to the rate of entry of NE into circulation, and this also depends on the uptake into nerve terminals. 26 In addition, sympathetic outflow differs among tissues and organs. 27 Therefore, one explanation for a reduced plasma concentration of NE and epinephrine in patients with DRD and normal response to cardiac sympathetic stimuli may be that local concentrations are still sufficient to produce an appropriate and adequate effect. Another explanation may be that long-term reductions in NE/epinephrine may have led to an adaptative increase sensitivity to NE and epinephrine in target tissues (eg, by receptor upregulation), a phenomenon well established in pharmacology of neurotransmitter function. 28 One difference was the raised baseline heart rate in patients with DRD compared with healthy control subjects. These findings raise 2 questions. In the face of reduced plasma concentrations of NE and epinephrine in patients with DRD, (1) how are the sympathoadrenal responses maintained and (2) why do these patients exhibit higher heart rates? An explanation for the higher heart rate could relate to an effect of reduced cardiac NO availability. Reduced NO bioavailability can lead to downregulation of parasympathetic neurotransmitter acetylcholine release, which would in turn be reflected in higher heart rate. 29 If this is the case, it suggests that nNOS (expressed in the heart) and eNOS (expressed in the endothelium) may have different sensitivities to BH4 deficiency.
In contrast to the findings in animal studies, echocardiographic studies in patients with DRD did not provide evidence for pulmonary hypertension or right ventricular hypertrophy. A potential explanation for the discrepancy with findings in the hph1 mouse is that the animal model was created by a chemical mutation that may have resulted in other defects in addition to the GCH1 deficiency. Alternatively, it is plausible to suggest that in humans, some mechanisms may exist to compensate for the deficiency of BH4 in the pulmonary vessels, as was seen in the systemic endothelium that do not exist in the mice. For example, other endothelial mediators such as endothelium-derived hyperpolarizing factor 30 or prostacyclins 31 may have been upregulated in the pulmonary as well as the systemic vasculature. Similarly, downregulation of endothelins 32 or a reduction in sympathetic response may have reduced the physiological antagonism of the pulmonary arterial bed. Last, it is possible that patients with DRD do not have pulmonary hypertension under normoxic conditions but are more susceptible to it under hypoxic conditions, though this could not be tested.
Because of the rarity of the condition, we were unable to conduct adequately powered genotype-phenotype analyses of vascular, autonomic, and cardiac functions because few individuals shared the same mutations. The heterogeneity of mutations does not preclude the possibility that some yetunstudied mutation might have a more overt cardiovascular or autonomic phenotype. However, irrespective of the specific mutation carried, all the patients studied had evidence of biopterin deficiency and all had lower blood levels of adrenaline and noradrenalin, indicating some common phenotypic defects in these patients. The absence of an overt cardiovascular phenotype is an important negative finding given the wide interest in possibility that acquired defects in the tetrahydrobiopterin pathway might contribute to a reduction in NO bioavailability and endothelial dysfunction in cardiovascular diseases in the general population.
In conclusion, in the first detailed and comprehensive investigation of its type, we found patients with inherited BH4 deficiency had broadly preserved endothelial, autonomic, and cardiac functions, suggesting that compensatory mechanisms may operate in these systems when BH4 is deficient from early life, in contrast with the acquired functional BH4 deficiency seen in endothelium in adult life in patients with atherosclerosis.
